@article{ATM16060,
author = {Matthen Mathew and Rachael A. Safyan and Catherine A. Shu},
title = {PD-L1 as a biomarker in NSCLC: challenges and future directions},
journal = {Annals of Translational Medicine},
volume = {5},
number = {18},
year = {2017},
keywords = {},
abstract = {The Food and Drug Administration (FDA) approval of immune checkpoint inhibitors has dramatically changed treatment paradigms for patients with advanced-stage or metastatic non-small cell lung cancer (NSCLC). Despite significant improvements in survival, the majority of NSCLC patients fail to respond to checkpoint inhibitors, notably antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), and uncertainties remain regarding how best to use these therapies in clinical practice. Given the risk of immune-related and other adverse effects associated with treatment, there is a need to identify biomarkers to predict which patients will and will not benefit.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/16060}
}